UNSPSC 51383101: Bermoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C18H16O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CWU66767HF, chemically known as 10,11-dihydro-alpha,8-dimethyl-11-oxo-dibenz(b,f)oxepin-2-acetic acid but generally known as bermoprofen, which bears US NIH Compound Identifier 54204. European Medicines Agency schedules Bermoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05782MIG.

UNSPSC 51383101 Bermoprofen, a Commodity code, shows limited direct alignment with recent state and local procurement activity. The three recent opportunities posted under this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program, and generic multi-source pharmaceuticals and OTC products — none of which centers on bermoprofen specifically. State and local governments do procure pharmaceuticals and medical supplies through competitive bidding and cooperative purchasing mechanisms, but the opportunities in the dataset appear to reflect broader pharmaceutical supply categories rather than a single active drug product. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of recent work spans naloxone kits for emergency response, direct manufacturer contracting for prescription programs, and commodity generic pharmaceutical and OTC product supply through authorized wholesalers.

Activity under this code appears concentrated in Texas and Minnesota, with a Florida county procurement also present. The Seminole County naloxone and drug deactivation systems IFB (Solicitation IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission's RFI (HHS0017013), posted April 3, 2026, explored vendor capabilities for direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and wholesaler channels. MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026, required manufacturers to supply through three authorized wholesalers with pricing effective July 1, 2026, and weighted price competitiveness at 75 percent of evaluation criteria. The bermoprofen code as described does not appear to drive substantial dedicated procurement activity at the state and local level based on recent opportunities.